DSMB. 1. What role, what responsabilities?;Les DSMB. 1. Quel rôle, quelles responsabilités?

Medecine/Sciences

Volumn 21, Issue 1, 2005, Pages 78-82

  Brun Buisson, Christian ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DATA ANALYSIS; DRUG EFFICACY; HUMAN; MEDICAL PRACTICE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS;

EID: 12344295869     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/200521178     Document Type: Review

References (13)

1. US department of health and human services. Food and drug administration. Draft guidance for clinical trials sponsors. On the establishment and operation of clinical trials data monitoring committees. Novembre 2001. http://www.fda.gov/cber/gdlns/clindatmon.htm
2. Armstrong PW, Furberg CD. Clinical trial data and safety monitoring boards. The search for a constitution. Circulation 1995; 91: 901-4.
3. DeMets DL, Pocock SJ, Julian DG. The agonising negative trend in monitoring of clinical trials. Lancet 1999; 354: 1983-8.
4. Lemaire F, Brun-Buisson C. Are institutional review boards effective in safeguarding patients in intensive care units? Curr Opin Anaesthesiol 2000; 13: 195-201.
5. Morse MA, Califf RM, Sugarman J. Monitoring and ensuring safety during clinical research. JAMA 2001; 285: 1201-5.
6. Mello MM, Studdert DM, Brennan TA. The rise of litigation in human subjects research. Ann Intern Med 2003; 139: 40-5.
7. Kalb PE, Koehler KG. Legal issues in scientific research. JAMA 2002; 287: 85-91.
8. McCloskey RV, Straube RC, Sanders C, et al. The CHESS trial study group. Treatment of septic shock with human monoclonal antibody HA-IA. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1994; 121: 1-5.
9. Wolkenstein P, Latarjet J, Roujeau JC, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998; 352: 1586-9.
10. Brun-Buisson C. Les DSMB. 2. De l'importance d'un DSMB efficace: exemples d'essais cliniques «à risque». Med Sci (Paris) 2005; 1 (sous presse).
11. Slutsky AS, Lavery JV. Data safety and monitoring boards. N Engl J Med 2004; 350: 1143-7.
12. Pocock S, White I. Trials stopped early: too good to be true? Lancet 1999; 353: 943-4.
13. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.